Targeting the cell cycle in the pursuit of novel chemotherapies against parasitic protozoa

Current Pharmaceutical Design

Volumn 14, Issue 9, 2008, Pages 917-924

  Grant, Karen M ^a  

^a LANCASTER UNIVERSITY   (United Kingdom)

Author keywords

Aurora kinase; Cell cycle; Cyclin dependent kinase; Glycogen synthase kinase; Leishmania; Plasmodium; Trypanosoma

Indexed keywords

5 IODO INDIRUBIN 3' MONOXIME; AURORA KINASE; AURORA KINASE INHIBITOR; AZAKENPAULLONE; CYCLIN DEPENDENT KINASE; CYCLIN DEPENDENT KINASE INHIBITOR; CYCLOPROPANECARBOXYLIC ACID [4 [4 (4 METHYL 1 PIPERAZINYL) 6 (5 METHYL 2H PYRAZOL 3 YLAMINO) 2 PYRIMIDINYLTHIO]PHENYL]AMIDE; FLAVOPIRIDOL; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3 INHIBITOR; HESPERADIN; HYMENIALDISINE; INDIRUBIN 3' MONOXIME; N [4 [6 METHOXY 7 (3 MORPHOLINOPROPOXY) 4 QUINAZOLINYLAMINO]PHENYL]BENZAMIDE; OLOMOUCINE; POLO LIKE KINASE; PROTEASOME INHIBITOR; PROTEIN SERINE THREONINE KINASE; ROSCOVITINE;

AFRICAN TRYPANOSOMIASIS; ANTINEOPLASTIC ACTIVITY; ANTIPROTOZOAL ACTIVITY; CELL CYCLE ARREST; CELL CYCLE REGULATION; DRUG STRUCTURE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; HUMAN; LEISHMANIA; LIFE CYCLE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMODIUM; PRIORITY JOURNAL; PROTOZOAL INFECTION; REVIEW; TOXOPLASMA; TRYPANOSOMA; VALIDATION PROCESS;

ANIMALS; ANTIPROTOZOAL AGENTS; CELL CYCLE; CYCLIN-DEPENDENT KINASES; DRUG DELIVERY SYSTEMS; GLYCOGEN SYNTHASE KINASES; HUMANS; PROTEIN-SERINE-THREONINE KINASES; PROTOZOA; PROTOZOAN INFECTIONS;

EID: 44349155924     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161208784041042     Document Type: Review

References (101)

1. Stevenson MM, Su Z, Sam H, Mohan K. Modulation of host responses to blood-stage malaria by interleukin-12: From therapy to adjuvant activity. Microbes Infect 2001; 3(1): 49-59.
2. Dubey JP, Lindsay DS, Speer CA. Structures of Toxoplasma gondii tachyzoites, bradyzoites, and sporozoites and biology and development of tissue cysts. Clin Microbiol Rev 1998; 11(2): 267-99.
3. Crews CM, Mohan R. Small-molecule inhibitors of the cell cycle. Curr Opin Chem Biol 2000; 4(1): 47-53.
4. Karp JE, Passaniti A, Gojo I, Kaufmann S, Bible K, Garimella TS, et al. Phase I and pharmacokinetic study of flavopiridol followed by 1-beta-D-arabinofuranosylcytosine and mitoxantrone in relapsed and refractory adult acute leukemias. Clin Cancer Res 2005; 11(23): 8403-12.
5. Benson C, White J, De Bono J, O'Donnell A, Raynaud F, Cruickshank C, et al. A phase I trial of the selective oral cyclin-dependent kinase inhibitor seliciclib (CYC202; R-Roscovitine), administered twice daily for 7 days every 21 days. Br J Cancer 2007; 96(1): 29-37.
6. Read M, Sherwin T, Holloway SP, Gull K, Hyde JE. Microtubular organization visualized by immunofluorescence microscopy during erythrocytic schizogony in Plasmodium falciparum and investigation of post-translational modifications of parasite tubulin. Parasitology 1993; 106(Pt 3): 223-32.
7. Ploubidou A, Robinson DR, Docherty RC, Ugbadoyi EO, Gull K. Evidence for novel cell cycle checkpoints in trypanosomes: Kinetoplast segregation and cytokinesis in the absence of mitosis. J Cell Sci 1999; 112(Pt 24): 4641-50.
8. Hammarton TC, Clark J, Douglas F, Boshart M, Mottram JC. Stage-specific differences in cell cycle control in Trypanosoma brucei revealed by RNA interference of a mitotic cyclin. J Biol Chem 2003; 278(25): 22877-86.
9. Broadhead R, Dawe HR, Farr H, Griffiths S, Hart SR, Portman N, et al. Flagellar motility is required for the viability of the blood-stream trypanosome. Nature 2006; 440(7081): 224-7.
10. Ha NC, Tonozuka T, Stamos JL, Choi HJ, Weis WI. Mechanism of phosphorylation-dependent binding of APC to beta-catenin and its role in beta-catenin degradation. Mol Cell 2004; 15(4): 511-21.
11. Kamura T, Hara T, Kotoshiba S, Yada M, Ishida N, Imaki H, et al. Degradation of p57Kip2 mediated by SCF Skp2-dependent ubiquitylation. Proc Natl Acad Sci USA 2003; 100(18): 10231-6.
12. Rudner AD, Murray AW. Phosphorylation by Cdc28 activates the Cdc20-dependent activity of the anaphase-promoting complex. J Cell Biol 2000; 149(7): 1377-90.
13. Guo Y, Yang K, Harwalkar J, Nye JM, Mason DR, Garrett MD, et al. Phosphorylation of cyclin D1 at Thr 286 during S phase leads to its proteasomal degradation and allows efficient DNA synthesis. Oncogene 2005; 24(16): 2599-612.
14. Berriman M, Ghedin E, Hertz-Fowler C, Blandin G, Renauld H, Bartholomeu DC, et al. The genome of the African trypanosome Trypanosoma brucei. Science 2005; 309(5733): 416-22.
15. Ivens AC, Peacock CS, Worthey EA, Murphy L, Aggarwal G, Berriman M, et al. The genome of the kinetoplastid parasite, Leishmania major. Science 2005; 309(5733): 436-42.
16. Gardner MJ, Hall N, Fung E, White O, Berriman M, Hyman RW, et al. Genome sequence or the human malaria parasite Plasmodium falciparum. Nature 2002; 419(6906): 498-511.
17. Hammarton TC, Engstler M, Mottram JC. The Trypanosoma brucei cyclin, CYC2, is required for cell cycle progression through G1 phase and for maintenance of procyclic form cell morphology. J Biol Chem 2004; 279(23): 24757-64.
18. Tu X, Wang CC. Pairwise knockdowns of cdc2-related kinases (CRKs) in Trypanosoma brucei identified the CRKs for G1/S and G2/M transitions and demonstrated distinctive cytokinetic regulations between two developmental stages of the organism. Eukaryot Cell 2005; 4(4): 755-64.
19. Tu X, Wang CC. The involvement of two cdc2-related kinases (CRKs) in Trypanosoma brucei cell cycle regulation and the distinctive stage-specilic phenotypes caused by CRK3 depletion. J Biol Chem 2004; 279(19): 20519-28.
20. Wang Y, Dimitrov K, Garrity LK, Sazer S, Beverley SM. Stage-specific activity of the Leishmania major CRK3 kinase and functional rescue of a Schizosaccharomyces pombe cdc2 mutant. Mol Biochem Parasitol 1998; 96(1-2): 139-50.
21. Le Roch K, Sestier C, Dorin D, Waters N, Kappes B, Chakrabarti D, et al. Activation of a Plasmodium falciparum cdc2-related kinase by heterologous p25 and cyclin H. Functional characterization of a P. falciparum cyclin homologue. J Biol Chem 2000; 275(12): 8952-8.
22. Merckx A, Le Roch K, Nivez MP, Dorin D, Alano P, Gutierrez GJ, et al. Identification and initial characterization of three novel cyclin-related proteins of the human malaria parasite Plasmodium falciparum. J Biol Chem 2003; 278(41): 39839-50.
23. Rangarajan R, Bei A, Henry N, Madamet M, Parzy D, Nivez MP, et al. Pbcrk-1, the Plasmodium berghei orrhologue of P. falciparum cdc-2 related kinase-1 (PfcrK- 1), is essential for completion of the intraerythrocytic asexual cycle. Exp Parasitol 2006; 112(3): 202-7.
24. Santori MI, Laria S, Gomez EB, Espinosa I, Galanti N, Tellez-Inon MT. Evidence for CRK3 participation in the cell division cycle of Trypanosoma cruzi. Mol Biochem Parasitol 2002; 121(2): 225-32
25. Robertson CD. The Leishmania mexicana proteasone. Mol Biochem Parasitol 1999; 103(1): 49-60.
26. Sancar A, Lindsey-Boltz LA, Unsal-Kacmaz K, Linn S. Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem 2004; 73: 39-85.
27. Pines J. Protein kinases and cell cycle control. Semin Cell Biol 1994; 5(6): 399-408.
28. Murray AW. Recycling the cell cycle: Cyclins revisited. Cell 2004; 116(2): 221-34.
29. Hershko A Roles of ubiquitin-mediated proteolysis in cell cycle control. Curr Opin Cell Biol 1997; 9(6): 788-99.
30. Lolli G, Johnson LN. CAK-Cyclin-dependent Activating Kinase: A key kinase in cell cycle control and a target for drugs? Cell Cycle 2005; 4(4): 572-7.
31. Kellogg DR. Weel-dependent mechanisms required for coordination of cell growth and cell division. J Cell Sci 2003; 116(Pt 24): 4883-90.
32. Trinkle-Mulcahy L, Lamond AI. Mitotic phosphatases: No longer silent partners. Curr Opin Cell Biol 2006; 18(6): 623-31.
33. Morgan DO. Cyclin-dependent kinases: Engines, clocks, and microprucessors. Annu Rev Cell Dev Bid 1997; 13: 261-91.
34. Moser BA, Russell P. Cell cycle regulation in Schizosaccharomyces pombe. Curr Opin Microbiol 2000; 3(6): 631-6.
35. Mendenhall MD, Hodge AE. Regulation of Cdc28 cyclin-dependent protein kinase activity during the cell cycle of the yeast Saccharomyces cerevisiae. Microbiol Mol Biol Rev 1998; 62(4): 1191-243.
36. Parsons M, Worthey EA, Ward PN, Mottram JC. Comparative analysis of the kinomes of three pathogenic trypanosomatids: Leishmania major, Trypanosoma brucei and Trypanosoma cruzi. BMC Genomics 2005; 6: 127.
37. Ward P, Equinet L, Packer J, Doerig C. Protein kinases of the human malaria parasite Plasmodium falciparum: The kinome of a divergent eukaryote. BMC Genomics 2004; 5(1): 79.
38. Doerig C, Endicott J, Chakrabarti D. Cyclin-dependent kinase homologues of Plasmodium falciparum. Int J Parasitol 2002; 32(13): 1575-85
39. Hammarion TC. Cell cycle regulation in Trynanosoma brucei. Mol Biochem Parasitol 2007; 153(1): 1-8.
40. Matthews KR. The developmental cell biology of Trynanosoma brucei. J Cell Sci 2005; 118(Pt 2): 283-90.
41. Grant KM, Hassan P, Anderson JS, Mottram JC. The crk3 gene of Leishmania mexicana encodes a stage-regulated cdc2-related histone H1 kinase that associates with p12. J Biol Chem 1998; 273(17): 10153-9.
42. Mottram JC, McCready BP, Brown KG, Grant KM. Gene disruptions indicate an essential function for the LmmCRK1 cdc2-related kinase of Leishmnania mexicana. Mol Microbiol 1996; 22(3): 573-83.
43. Mottram JC, Smith G. A family of trypanosome cdc2-related protein kinases. Gene 1995; 162(1): 147-52.
44. Gomez EB, Kornblihtt, AR, Tellez-Inon MT. Cloning of a cdc2-related protein kinase from Trypanosoma cruzi that interacts with mammalian cyclins. Mol Biochem Parasitol 1998; 91(2): 337-51.
45. Gomez EB, Samon ML, Laria S, Engel TC, Swindle J, Eisen H, et al. Characterization of the Trypanosoma cruzi Cdc2p-related protein kinase 1 and identification of three novel associating cyclins. Mol Biochem Parasitol 2001; 113(1): 97-108.
46. Khan F, Tang J, Qin CL, Kim K. Cyclin-dependent kinase TPK2 is a critical cell cycle regulator in Toxoplasma gondii. Mol Microbiol 2002; 45(2): 321-32.
47. Kinnaird J, Logan M, Tait A, Langsicy G. TaCRK3 encodes a novel Theileria annulata protein kinase with motifs characteristic of me family of eukaryotic cyclin dependent kinases: A comparative analysis of its expression with TaCRK2 during the parasite life cycle. Gene 2001; 279(2): 1271-35.
48. Kinnnird JH, Bumstend JM, Mann DJ, Rynn R, Shirley MW, Shiels BR, et al. EtCRK2, a cyclin-dependeni kinase gene expressed during the sexual and asexual phases of the Eimeria tenelia life cycle. Int J Parasitol 2004; 34(6): 683-92.
49. Kinnaird JH, Logan M, Kirvar E, Tait A, Carrington M. The isolation and characterization of genomic and cDNA clones coding for a cdc2-rela-ted Own (ThCRK2) from the bovine protozoan parasite Theileria. Mol Microbiol 1996; 22(2): 293-302.
50. Hassan P, Fergusson D, Grant KM, Mottram X. The CRK3 protein kinase is essential for cell cycle progression of Leishmania mexicana. Mol Biochem Parasitol 2001; 113(2): 189-98.
51. Van Hellemond JJ, Neuville P, Schwarz RT, Matthews KR, Mottram JC. Isolation of Trypanosoma brucei CYC2 arid CYC3 cyclin genes by rescue of a yeast G(1) cyclin mutant. Functional characterization of CYC2. J Biol Chem 2000; 275(12): 8315-23.
52. Li JL, Robson KJ, Chen JL, Targett GA, Baker DA. Pfmrk, n MO15-related protein kinase from Plasmodium falciparum. Gene cloning, sequence, stage-specific expression and chromosome localization. Eur J Biochem 1996; 241(3): 805-13.
53. Ross-Macdonald PB, Graeser R, Kappes B, Franklin R, Williamson DH. Isolation and expression of a gene specifying a cdc2-like protein kinase from the human malaria parasite Plasmodium falciparum. Eur J Biochem 1994; 220(3): 693-701.
54. Graeser R, Franklin RM, Kappes B. Mechanisms of activation of the cdc2-related kinase PfPK5 from Plasmodium falciparum. Mol Biochem Parasitol 1996; 79(1): 125-7.
55. Knockaert M, Greengard P, Meijer L. Pharmacological inhibitors of cyclin-dependent kinases. Trends Pharmacol Sci 2002; 23(9): 417-25.
56. Waters NC, Woodard CL, Prigge ST. Cyclin H activation and drug susceptibility of the Pfmrk cyclin dependent protein kinase from Plasmodium falciparum. Mol Biochem Parasiiol 2000; 107(1): 45-55.
57. Graeser R, Wernli B, Franklin RM, Kappes B. Plasmodium falcinum protein kinase 5 and the malarial nuclear division cycles. Mol Biochem Parasitol 1996; 82(1): 37-49.
58. Naughton JA, Bell A. Studies on cell-cycle synchronization in the asexual erythrocytic stages of Plasmodium falciparum. Parasitology 2007; 134(Pt 3): 331-7.
59. Harmse L, van Zyl R, Gray N, Schultz P, Leclerc S, Meijer L, et al. Structure-activithy relationships and inhibitory effects of various purine derivatives on the in vitro growth of Plasmodium falciparum. Biochem Pharmacol 2001; 62(3): 341-8.
60. Holton S, Merckx A, Burgess D, Doerig C, Noble M, Endicott J. Structures of P. falciparum PfPK5 test the CDK regulation paradigm and suggest mechanisms of small molecule inhibition. Structure 2003; 11(11): 1329-37.
61. Grant KM, Dunion MH, Yardley V, Skaltsounis AL, Marko D, Eisenbrand G, et al. Inhibitors of Leishmania mexicana CRK3 cyclin-dependent kinase: Chemical library screen and antileishmanial activity. Antimicrob Agents Chemother 2004; 48(8): 3033-42.
62. Leclerc S, Garnier M, Hoessel R, Marko D, Bibb JA, Snyder GL, et al. Indirubins inhibit glycogen synthase kinase-3 beta and CDK5/p25, two protein kinases involved in abnormal tau phosphorylation in Alzheimer's disease. A property common to most cyclin-dependent kinase inhibitors? J Biol Chem 2001; 276(1): 251-60.
63. Hoessel R, Leclerc S, Endicott JA, Nobel ME, Lawrie A, Tunnah P, et al. Indirubin, the active constituent of a Chinese antileukaemia medicine, inhibits cyclin-dependent kinases. Nat Cell Biol 1999; 1(1): 60-7.
64. Wells C, McNae I, Walkinshaw M, Westwood NJ, Grant KM. The selective biological activity of indirubin-based inhibitors: Applications in parasitology. in: Meijer L, Guyard N, Skaltsounis LA, Eisenbrand G Eds, Indirubin, the red shade of indigo. Life in Progress ed. Roscoff, France: Station Biologique 2006; 259-67.
65. Davies TG, Tunnah P, Meijer L, Marko D, Eisenbrand G, Endicott JA, et al. Inhibitor binding to active and inactive CDK2: The crystal structure of CDK2-cyclin A/indirubin-5-sulphonate. Structure 2001; 9(5): 389-97.
66. Peng Y, Keenan SM, Welsh WJ. Structural model of the, Plasmodium CDK, Pfmrk, a novel target for malaria therapeutics. J Mol Graph Model 2005; 24(1): 72-80.
67. Xiao Z, Waters NC, Woodard CL, Li Z, Li PK. Design and synthedsis of Pfmrk inhibitors as potential antimalarial agents. Bioorg Med Chem Lett 2001; 11(21): 2875-8.
68. Keenan SM, Geyer JA, Welsh WJ, Prigge ST, Waters NC. Rational inhibitor design and iterative screening in the identification of selective plasmodial cyclin dependent kinase inhibitors. Comb Chem High Throughput Screen 2005; 8(1): 27-38.
69. Grimes CA, Jope RS. The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 2001; 65(4): 391-426.
70. Diehl JA, Cheng M, Roussel MF, Sherr CJ. Glycogen synthase kinase-3beta regulates cyclin D1 proteolysis and subcellular localization. Genes Dev 1998; 12(22): 3499-511.
71. Wakefield JG, Stephens DJ, Tavare JM. A role for glycogen synthase kinase-3 in mitotic spindle dynamics and chromosome alignment. J Cell Sci 2003; 116(Pt 4): 637-46.
72. Kassir Y, Rubin-Bejerano I, Mandel-Gutfreund Y. The Saccharomyces cerevisiae GSK-3 beta homologs. Curr Drug Targets 2006; 7(11): 1455-65.
73. Wilson NF, Lefebvre PA. Regulation of flagellar assembly by glycogen synthase kinase 3 in Chlamydomonas reinhardtii. Eukaryot Cell 2004; 3(5): 1307-19.
74. Cohen P, Goedert M. GSK3 inhibitors: Development and therapeutic potential. Nat Rev Drug Discov 2004; 3(6): 479-87.
75. Droucheau E, Primot A, Thomas V, Mattei D, Knockaert M, Richardson C, et al. Plasmodium falciparum glycogen synthase kinase-3: molecular model, expression, intracellular localisation and selective inhibitors. Biochim Biophys Acta 2004; 1697(1-2): 191-96.
76. Qin CL, Tang J, Kim K. Cloning and in vitro expression of TPK3, a Toxoplasma gondii homologue of shaggy/glycogen synthase kinase-3 kinases. Mol Biochem Parasitol 1998; 93(2): 273-83.
77. Carmena M, Earnshaw WC. The cellular geography of aurora kinases. Nat Rev Mol Cell Biol 2003; 4(11): 842-54.
78. Tang CJ, Lin CY, Tang TK. Dynamic localization and functional implications of Aurora-C kinase during male mouse meiosis. Dev Biol 2006- 290(2): 398-410.
79. Kufer TA: Nigg EA, Sillje HH. Regulation of Aurora-A kinase on the mitotic spindle. Chromosoma, 2003; 112(4): 159-63.
80. Murnion ME, Adams RR, Callister DM, Allis CD, Earnshaw WC, Swedlow JR. Chromatin-associated protein phosphatase 1 regulates aurora-B -and histone H3 phosphorylation. J Biol Chem 2001; 276(28): 26656-65.
81. Castro A, Arlot-Bonnemains Y, Vigneron S, Labbe JC, Prigent C, Lorca T. APC/Fizzy-Related targets Aurora-A kinase for proteolysis. EMBO Rep 2002; 3(5): 457-62.
82. Mortlock AA, Keen NJ, Jung FH, Heron NM, Foote KM, Wilkinson RW, et al. Progress in t~e development of selective inhibitors of aurora kinases. Curr Topics Med Chem 2005; 5(8): 807-21.
83. Harrington EA, Bebbington D, Moore J, Rasmussen RK, Ajose-Adeogun AO, Nakayama T, et al. VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10(3): 262-7.
84. Ditchfield C, Johnson VL, Tighe A, Ellston R, Haworth C, Johnson T, et al. Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores. J Cell Biol 2003; 161(2): 267-80.
85. Tu X, Kumar P, Li Z, Wang CC. An aurora kinase homologue is involved in regulating both mitosis and cytokinesis in Trypanosoma brucei. J Biol Chem 2006; 281(14): 9677-87.
86. Siman-Tov MM, Ivens AC, Jaffe CL. Identification and cloning of Lmairk, a member of the Aurora/Ipl1p protein kinase family, from the human protozoan parasite Leishmania. Biochim Biophys Acta 2001; 1519(3): 241-5.
87. Li Z, Wang CC. Changing roles of aurora-B kinase in two life cycle stages of Trypanosoma brucei. Eukaryot Cell 2006; 5(7): 1026-35
88. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer 2006; 6(4): 321-30.
89. Ishii Y, Waxman S, Germain D. Targeting the ubiquitin-proteasome pathway in cancer therapy. Anticancer Agents, Med Chem 2007; 7(3): 359-65.
90. Nigg EA. Polo-like kinases: Positive regulators of cell division from start to finish. Curr Opin Cell Biol 1998; 10(6): 776-83.
91. Eckerdt F, Strebhardt K. Polo-like kinase 1: Target and regulator of anaphase-promoting complex/cyclosome-dependent proteolysis. Cancer Res 2006; 66(14): 6895-8.
92. Yoshida S, Kono K, Lowery DM, Bartolini S, Yaffe MB, Ohya Y, et al. Polo-like kinase Cdc5 controls the local activation of Rho1 to promote cytokinesis. Science 2006; 313(5783): 108-11.
93. Kumar P, Wang CC. Dissociation of cytokinesis initiation from mitotic control in a eukaryote. Eukaryot Cell 2006; 5(1): 92-102.
94. Hammarton TC, Kramer S, Tetley L, Boshart M, Mottram JC. Trypanosoma brucei Polo-like kinase is essential for basal body duplication, kDNA segregation and cytokinesis. Mol Microbiol 2007; 65(5): 1229-48.
95. Reed SI. The ubiquitin-proteasome pathway in cell cycle control. Results Probl Cell Differ 2006; 42: 147-81.
96. Montagut C, Rovira A, Albanell J. The proteasome:a novel target for anticancer therapy. Clin Transl Oncol 2006; 8(5): 313-7.
97. Lindenthal C, Weich N, Chia YS, Heussler V, Klinkert MQ. The proteasome inhibitor MLN-273 blocks exoerythrocytic and erythrocytic development of Plasmodium parasites. Parasitology 2005; 131(Pt 1): 37-44.
98. Gantt SM, Myung JM, Briones MR, Li WD, Corey EJ, Omura S, et al. Proteasome inhibitors block development of Plasmodium spp. Antimicrob Agents Chemother 1998; 42(10): 2731-80.
99. Myrianthopoulos V, Magiatis P, Ferandin Y, Skaltsounis AL, Meijer L, Mikros E. An integrated computational approach to the phenomenon of potent and selective inhibition of aurora kinases B and C by a series of 7-substituted indirubins. J Med Chem 2007; 50(17): 4027-37.
100. Rossi KA, Markwalder JA, Seitz SP, Chang CH, Cox S, Boisclair MD, et al. Understanding and modulating cyclin-dependent kinase inhibitor specificity: Molecular modeling and biochemical evaluation of pyrazolopyrimidinones as CDK2/cyclin A and CDK4/cyclin D1 inhibitors. J Comput Aided Mol Des 2005; 19(2): 111-22.
101. Sebolt-Leopold JS, English JM. Mechanisms of drug inhibition of signalling molecules. Nature 2006; 441(7092): 457-62.